Phase 3 Haemophilia Trial, Recruiting NCT06833983 Sponsor: Gritgen Therapeutics Co., Ltd. Condition: Haemophilia
Back to Haemophilia

Phase 3 Haemophilia Trial, Recruiting

NCT06833983
Recruiting Phase 3

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who understand the purpose and risks of the study and have given their formal written consent to participate
  • People who are male and between 19 and 65 years old at the time of signing the consent form
  • People who have a confirmed diagnosis of hemophilia A, based on their medical history and laboratory test results
  • People who have previously used Factor VIII (FVIII) products for at least 150 treatment days before joining the study
  • People who have no prior history of developing inhibitors (antibodies that block) Factor VIII
  • People who agree to use a reliable barrier method of contraception from the time of signing the consent form
  • People who are willing and able to attend scheduled visits and follow the study procedures as planned

Who may not be able to join:

  • People who have a bleeding disorder that is not related to hemophilia A
  • People whose liver function tests came back abnormal during the screening period
  • People whose general laboratory test results were abnormal during the screening period
  • People who have an active or long-term hepatitis B or hepatitis C infection, or who are currently receiving antiviral treatment for hepatitis B or C
  • People who have an active disease affecting the immune system throughout the body

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: +8613817454595

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 3
Sponsor
Gritgen Therapeutics Co., Ltd.
Registry
ClinicalTrials.gov
Start date
31 March 2025
Est. completion
30 November 2026

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Annualized Bleeding Rate (ABR)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov